


CLAIMS

1. A conjugate according to Formula II, or a salt thereof:



(II)


wherein X is  , or  , or methylene, or bond;

Y is a linker comprising a disulfide; and

Z is a flavagline anti-cancer drug.


2. The conjugate of claim 1, wherein the flavagline anti-cancer drug comprises FLV-1, FLV-3, a derivative or analog thereof, or a combination thereof.

3. The conjugate of any one of claims 1-2, wherein the linker comprises the following:




(7) .

4. The conjugate of any one of claims 1-3, selected from the following:



(8) , and



(9) .

5. A composition comprising the conjugate of any one of claims 1-4 and a pharmaceutically acceptable carrier.

6. Use of the conjugate of any one of claims 1-4 in the manufacture of a medicament for treating cancer in a subject.

7. The use of claim 6, wherein the flavagline anti-cancer drug localizes or travels to the cytoplasm or organelle of the tumor or cancer cell.

8. The use of claim 6, wherein the conjugate or flavagline anti-cancer drug is selective for cancer cells in the subject.

9. The use of claim 6, wherein the conjugate or flavagline anti-cancer drug is incorporated into at least about 2-fold more tumor or cancer cells than healthy cells.

10. The use of any one of claims 6-9, wherein the cancer is selected from melanoma, brain cancer, lung cancer, adrenal cancer, liver cancer, renal or kidney cancer, pancreatic cancer, esophageal cancer, gastric cancer, stomach cancer, colon cancer, colorectal cancer, anal cancer, prostate cancer, ovarian cancer, breast cancer, cervical cancer, lymphoma, leukemia, myeloma, hematologic cancer, hepatocarcinoma, retinoblastoma, glioma, sarcoma, blastoma, squamous cell carcinoma, and adenocarcinoma.

11. The use of any one of claims 6-10, wherein the subject is human.